Refine by
Neurodegenerative Disorder Equipment Supplied In Europe
10 equipment items found
Manufactured by:Addex Therapeutics based inGeneva, SWITZERLAND
mGlu3 PAM for the treatment of neurodegenerative disorders. We are developing mGlu3 PAM as a novel orally available treatment for neurodegenerative disorders. We are currently optimizing multiple chemical series of highly selective mGlu3 PAMs, with compounds in early lead optimization. ...
Manufactured by:BioArctic AB based inStockholm, SWEDEN
Research to develop new antibodies for treating neurodegenerative disorders is under way at BioArctic. the ND3014 project aims to develop selective antibody treatments targeting TDP-43, a protein that is believed to play a crucial role in the development of the rare neurodegenerative disease ALS (amyotrophic lateral ...
by:Gain Therapeutics, Inc. based inBethesda, MARYLAND (USA)
Parkinson’s disease is a neurodegenerative disorder that affects more than 6 million people worldwide. In most cases, the exact cause of Parkinson’s disease is unknown; however, mutations in GBA1, the gene that encodes the beta-glucocerebrosidase (GCase) enzyme, have been tied to the disease. ...
by:Gain Therapeutics, Inc. based inBethesda, MARYLAND (USA)
Krabbe disease is a severe neurodegenerative disorder caused by mutations in GALC, the gene that encodes the galactosylceramidase (GALC) enzyme. These mutations cause GALC misfolding and dysfunction, which leads to the toxic buildup up fats in the central nervous system (CNS) and ultimately leads to the demyelination and death of neurons. ...
Manufactured by:BioArctic AB based inStockholm, SWEDEN
BioArctic has developed a technology platform that has proven to be successful when the company’s first drug candidate was developed, the antibody BAN2401 for Alzheimer´s disease. Our mission is to improve quality of life for patients suffering from Central Nervous System (CNS) disorders. Patients with neurodegenerative disorders like ...
by:betaSENSE based in, GERMANY
betaSENSE has developed a cutting-edge platform technology leveraging the principles of infrared spectroscopy to advance diagnostics in neurodegenerative disorders. The technology, known as betaSENSE, utilizes differential spectroscopy to detect minute changes between states of a sample by subtracting absorption spectra, thereby highlighting protein signals such ...
by:Gain Therapeutics, Inc. based inBethesda, MARYLAND (USA)
Protein misfolding is the root of many diseases, including lysosomal storage disorders and neurodegenerative ...
by:Sibylla Biotech S.p.A. based inVerona, ITALY
The PPI-FIT (Pharmacological Protein Inactivation by Folding Intermediate Targeting) technology, of which Sibylla is the exclusive licensee, is a paradigm shift in rational drug design. The basic task of drug design is to find a small molecule able to bind a biological target -such as a protein- so to modulate or block its activity. So far, almost all drug design has focused on the native ...
Manufactured by:Lys Therapeutics based inCAEN, FRANCE
Glunomab / Glunozumab®: a monoclonal antibody counteracting the strong toxicity triggered by the interaction of an endogenous protease, tissue plasminogen activator (tPA) with NMDA receptors ...
Manufactured by:Thermo Scientific - LC/MS GC GC/MS based in, MASSACHUSETTS (USA)
The Ion GeneStudio S5 systems are designed to enable a broad range of targeted next-generation sequencing (NGS) applications with speed and ...